Modern cancer therapy has successfully cured many cancers and converted a terminal
illness into a chronic disease. Because cancer patients often have coexisting heart …

Answer questions and earn CME/CNE Cancer and heart disease are the leading causes of
morbidity and mortality in the industrialized world. Modern treatment strategies have led to …

ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

Serum biomarkers are an important tool in the baseline risk assessment and diagnosis of
cardiovascular disease in cancer patients receiving cardiotoxic cancer treatments. Increases …

Background—Three types of anthracycline-induced cardiotoxicities are currently
recognized: acute, early-onset chronic, and late-onset chronic. However, data supporting …

Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer
receiving anthracyclines - de Baat, EC - 2022 | Cochrane Library Skip to Content Cookies Our …

Survivors of childhood cancer treated with anthracycline chemotherapy or chest radiation
are at an increased risk of developing congestive heart failure. In this population, congestive …

Advances in cancer therapy have resulted in significant improvement in long-term survival
for many types of cancer but have also resulted in untoward side effects associated with …

1928 Circulation October 22, 2013 mental health, functional status, activity limitations,
cancerrelated pain, and cancer-related anxiety) declined moderately to severely in 44%. 5 …

Doxorubicin (Dox) is a cytotoxic drug widely incorporated in various chemotherapy
protocols. Severe side effects such as cardiotoxicity, however, limit Dox application …